Research programme: serotonin/histamine antagonists - Evolutec

Drug Profile

Research programme: serotonin/histamine antagonists - Evolutec

Alternative Names: EV 598; rEV 598

Latest Information Update: 19 Mar 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Evolutec
  • Class Antiemetics; Antineoplastics; Glycoproteins
  • Mechanism of Action Histamine release inhibitors; Serotonin receptor antagonists; Serotonin release inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant carcinoid syndrome; Nausea and vomiting

Most Recent Events

  • 25 Oct 2006 Suspended - Preclinical for Emesis in United Kingdom (Parenteral)
  • 14 Mar 2006 EV 598 is available for licensing (http://www.evolutec.co.uk)
  • 05 Sep 2005 This compound is still in active development - (BIO-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top